
Libido and erection quality are separate clinical concerns. See how testosterone evidence, broader assessment and repeat testing inform their evaluation.

Libido describes sexual desire while erectile function concerns getting and maintaining an erection, a distinction that matters when assessing testosterone status and other possible contributors to sexual difficulties.
This article is for informational purposes only and is not medical advice. Personal diagnosis and treatment decisions belong with a qualified clinician.
Libido means sexual desire or interest in sex. A concern about libido asks whether that interest has changed, rather than whether an erection can be achieved or maintained. Those questions address different parts of sexual function even when both concerns are present.
The European Association of Urology (EAU) guidance recommends asking about desire alongside erection characteristics and other sexual concerns. Its assessment also includes arousal, ejaculation and orgasm. These are separate areas to discuss rather than interchangeable measures of whether sexual function is satisfactory.
Testosterone is relevant to desire. The EAU's hypogonadism guidance identifies improved libido as a possible benefit of testosterone therapy in men with hypogonadism, or testosterone deficiency. That makes reduced desire a relevant part of a hormone assessment.
A useful clinical description separates several questions:
This is more informative than treating all sexual changes as one symptom. The distinction between sexual drive and erection mechanics helps explain why an assessment should identify the particular concern before interpreting a hormone result.
It also gives treatment evidence a clearer meaning. A study reporting improved desire is answering a different question from a study reporting improved erection rigidity or duration.
Erectile function concerns a physical response: getting an erection and keeping it sufficiently firm. Desire concerns sexual interest. Reporting difficulty with that physical response does not, by itself, describe how much interest in sex a man has.
EAU guidance recommends asking about erection rigidity and duration, including morning erections. These questions sit alongside the assessment of desire and other sexual-function concerns. The guideline also identifies validated questionnaires that assess different areas of sexual function.
Unlike a question focused on interest in sex, an erection assessment must consider several possible physical and psychological pathways. The EAU lists vascular, hormonal and neurological causes. It also identifies anatomical, drug-induced and psychological causes, noting that several pathways may coexist.
Its listed contributors include:
These categories guide a clinical investigation. They do not establish the cause of any particular man's symptoms simply because he has a condition or takes a medicine on the list.
The guideline also recommends considering life stressors and thoughts related to sexual performance. Including those questions alongside medical history allows psychological and physical contributors to be considered together rather than treated as competing explanations.
Morning erections have a place in this history, but the guideline places them inside a wider assessment. They are not a replacement for discussing erection quality during sexual activity or reviewing other symptoms and health conditions. This is the context behind assessing morning erections as one part of the clinical picture.
Testosterone therapy does not have an identical relationship with every area of sexual function. The clearest way to understand the evidence is to keep desire and erectile-function outcomes separate, then consider the men in whom those outcomes were studied.
The EAU's review of testosterone treatment evidence reports that a meta-analysis of placebo-controlled trials found improvements in erectile-function scores. Improvements were greater among men with more severe hypogonadism than among men with milder hypogonadism. This finding concerns men with testosterone deficiency rather than men with sexual difficulties regardless of hormone status.
The same guideline describes some trials in men with type 2 diabetes in which testosterone therapy improved sexual desire and satisfaction without improving erectile function. These findings show why a positive result for one sexual outcome should not be presented as a positive result for every outcome.
Another trial involved men with low testosterone and impaired glucose tolerance or newly diagnosed type 2 diabetes. In that population, the guideline reports improvements in sexual function and erectile dysfunction. The results therefore differed across the populations described.
The central evidence limitation is that these findings cannot support a promise that testosterone will resolve erection difficulties for every man with a low result. Population differences and separate outcome measures matter. The practical reading is to ask which symptom improved and in whom, rather than treating “better sexual function” as a single result.
EAU hypogonadism guidance says testosterone therapy can improve libido and milder erectile dysfunction in men with hypogonadism. It reports no evidence supporting its use to treat sexual dysfunction in men with normal testosterone, sometimes described as eugonadal men.
That distinction makes hormone status clinically relevant without making it the whole explanation. Testosterone deficiency and other contributors to erection difficulties need to be weighed within the same assessment.
It also sets a more precise expectation for treatment discussions. Improved interest in sex is a meaningful outcome, but it should not be counted as proof that erection quality has improved. Likewise, an erectile-function score does not describe every aspect of desire or sexual satisfaction.
The EAU recommends a broad erectile-dysfunction assessment rather than a testosterone test alone. Its approach combines a detailed medical and sexual history with a focused physical examination and relevant laboratory testing.
The history helps establish what needs explaining:
This is not a choice between a “hormonal” assessment and a “non-hormonal” assessment. The guideline's framework allows clinicians to consider several contributing pathways at once. That matters because identifying one relevant factor does not mean the other questions have been answered.
EAU erectile-dysfunction guidance includes glucose or HbA1c and lipids in the laboratory evaluation. It also includes early-morning total testosterone measured fasting. Calculated free testosterone may sometimes help corroborate the total testosterone result, according to the guideline.
For suspected late-onset hypogonadism, the EAU bases diagnosis on compatible symptoms or signs together with consistently low morning testosterone. It recommends repeating a low result on separate occasions before treatment. A single low measurement is therefore not the same as a confirmed diagnosis.
These recommendations connect the laboratory result to the clinical concern. The relevant question is not simply whether a number is low, but whether the symptoms and confirmed findings support testosterone deficiency. Understanding why testosterone testing involves timing and confirmation provides useful background for that discussion.
The treatment implications follow from the assessment. EAU guidance supports a potential role for testosterone therapy in men with hypogonadism, while the erectile-dysfunction guidance calls for attention to the wider set of possible contributors.
A useful way to interpret proposed benefits is to name the outcome:
Keeping those outcomes separate avoids treating improvement in one area as an answer to every sexual concern. It also keeps expectations tied to the evidence rather than to the broad label of a testosterone treatment.
For an individual man, decisions about treatment belong with a qualified clinician who can weigh the symptom history and examination against the laboratory findings. The educational goal is to make that discussion clearer, not to turn a symptom or test result into a self-directed hormone plan.
Libido and erectile function belong in the same clinical picture, but each needs its own assessment and neither should be reduced to a testosterone number alone.
Treating desire, erections and a testosterone result as interchangeable can turn a complex assessment into a misleading single-number story. Testostra places free versus total testosterone and SHBG in an evidence-led context, helping readers understand hormone reports without offering personal diagnoses or treatment protocols.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra